The role of calcineurin inhibitors in the management of lichen sclerosus

American Journal of Clinical Dermatology

Volumn 10, Issue 5, 2009, Pages 313-318

  Yesudian, Paul D ^a  

^a GLAN CLWYD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; ESTROGEN; HLA ANTIGEN CLASS 2; PIMECROLIMUS; PROGESTERONE; SCLEROPROTEIN; STEROID 5ALPHA REDUCTASE; TACROLIMUS; TESTOSTERONE; TRANSCRIPTION FACTOR NFAT;

ANGIOGENESIS; APPLICATION SITE IRRITATION; APPLICATION SITE REACTION; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BALANOPOSTHITIS; CLINICAL TRIAL; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GENETIC ASSOCIATION; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; IMMUNE DYSREGULATION; IMMUNOGENETICS; IMMUNOGENICITY; IMMUNOPATHOGENESIS; INFECTION; INJURY; LICHEN SCLEROSUS ET ATROPHICUS; PAIN; PATHOGENESIS; PRECANCER; PRIORITY JOURNAL; PRURITUS; REMISSION; REVIEW; SKIN BURNING SENSATION; T LYMPHOCYTE;

ADMINISTRATION, CUTANEOUS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CALCINEURIN; DERMATOLOGIC AGENTS; GLUCOCORTICOIDS; HUMANS; LICHEN SCLEROSUS ET ATROPHICUS;

EID: 68949154362     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11310750-000000000-00000     Document Type: Review

References (66)

1. Meffert JJ, Davis BM, Grimwood RE. Lichen sclerosus. J Am Acad Dermatol 1995; 32: 393-416
2. Neill SM, Tatnall FM, Cox NH., British Association of Dermatologists. Guidelines for the management of lichen sclerosus. Br J Dermatol 2002; 147: 640-649
3. Bohm M, Frieling U, Luger TA, et al. Successful treatment of anogenital lichen sclerosus with topical tacrolimus. Arch Dermatol 2003; 139: 922-924
4. Kunstfeld R, Kirnbauer R, Stingl G, et al. Successful treatment of vulvar lichen sclerosus with topical tacrolimus. Arch Dermatol 2003; 139: 850-852
5. Novak N, Kwiek B, Bieber T. The role of topical immunomodulators in the immunological network of atopic dermatitis. Clin Exp Dermatol 2005; 30:160-164
6. Yesudian PD, Sugunendran H, Bates CM, et al. Lichen sclerosus. Int J STD AIDS 2005; 16: 465-473
7. Oyama N, Chan I, Neill SM, et al. Autoantibodies to extracellular matrix protein 1 in lichen sclerosus. Lancet 2003; 362: 118-123
8. Meyrick Thomas RH, Ridley CM, McGibbon DH, et al. Lichen sclerosus et atro-phicus and autoimmunity: a study of 350 women. Br J Dermatol 1988; 118:41-46
9. Smith YR, Haefner HK. Vulval lichen sclerosus: pathophysiology and treatment. Am J Clin Dermatol 2004; 5: 105-125
10. Meffert JJ, Grimwood RE. Lichen sclerosus et atrophicus appearing in an old burn scar. J Am Acad Dermatol 1994; 31: 671-673
11. Bunker CB. Male genital lichen sclerosus and tacrolimus. Br J Dermatol 2007; 157: 1079-1080
12. Bunker CB. Management of penile dermatoses. Expert Rev Dermatol 2006; 1: 241-260
13. Val I, Almeida G. An overview of lichen sclerosus. Clin Obstet Gynecol 2005; 48: 808-817
14. Marren P, Cherry C, Day A. Lichen sclerosus: the patients, the hormonal influences and the disease impact [abstract]. Br J Dermatol 1995; 133: 21
15. Friedrich Jr EG, Kalra PS. Serum levels of sex hormones in vulvar lichen sclerosus, and the effect of topical testosterone. N Engl J Med 1984; 310:488-491
16. Cox NH, Mitchell JN, Morley WN. Lichen sclerosus et atrophicus in non-identical female twins [letter]. Br J Dermatol 1986; 115: 743
17. Marren P, Yell J, Charnock FM, et al. The association between lichen sclerosus and the antigens of the HLA system. Br J Dermatol 1995; 132: 197-203
18. Azurdia RM, Luzzi GA, Byren I, et al. Lichen sclerosus in adult men: a study of HLA associations and susceptibility to autoimmune disease. Br J Dermatol 1999; 140: 79-83
19. Clay FE, Cork MJ, Tarlow JK, et al. Interleukin 1 receptor antagonist gene polymorphism associated with lichen sclerosus. Hum Genet 1994; 94: 407-410
20. Scrimin F, Rustja S, Radillo O, et al. Vulvar lichen sclerosus: an immunologic study. Obstet Gynecol 2000; 95: 147-150
21. Cantwell Jr. AR. Histologic observations of pleomorphic, variably acid-fast bacteria in scleroderma, morphea, and lichen sclerosus et atrophicus. Int J Dermatol 1984; 23: 45-52
22. Tuffanelli D. Do some patients with morphea and lichen sclerosus et atrophicus have a Borrelia infection? Am J Dermatopathol 1987; 9: 371-373
23. Drut RM, Gomez M, Drut R, et al. Human papilloma virus is present in some cases of childhood penile lichen sclerosus: an in-situ hybridization and SP-PCR study. Pediatr Dermatol 1998; 15: 85-90
24. Hampton PJ, Reynolds NJ. Calcineurin inhibitors for the treatment of skin disease: how do they work? Clin Exp Allergy 2005; 35: 549-550
25. Patel TS, Greer SC, Skinner RB. Cancer concerns with topical immunomodulators in atopic dermatitis. Am J Clin Dermatol 2007; 8: 189-194
26. Rustin MH. The safety of tacrolimus for the treatment of atopic dermatitis: a review. Br J Dermatol 2007; 157: 861-873
27. Strittmatter HJ, Hengge UR, Blecken SR. Calcineurin antagonists in vulval lichen sclerosus. Arch Gynecol Obstet 2006; 274: 266-270
28. Wollenberg A, Sharma S, von Bubnoff D, et al. Tacrolimus (FK 506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol 2001; 107: 519-525
29. Meingassner JG, Aschauer H, Stuetz A, et al. Pimecrolimus permeates less than tacrolimus through normal, inflamed or corticosteroid-penetrated skin. Exp Dermatol 2005; 14: 752-757
30. Wollina U. The role of topical calcineurin inhibitors for skin disease other than atopic dermatitis. Am J Clin Dermatol 2007; 8: 157-173
31. Meurer M, Fartasch M, Albrecht G, et al. Long-term efficacy and safety of pimecrolimus cream 1 % in adults with moderate atopic dermatitis. Dermatology 2004; 208: 365-372 (Pubitemid 38736667)
32. Assmann T, Becker-Wegerich P, Grewe M, et al. Tacrolimus ointment for the treatment of vulvar lichen sclerosus. J Am Acad Dermatol 2003; 48:935-937
33. Matsumoto Y, Yamamoto T, Isobe T, et al. Successful treatment of vulvar lichen sclerosus in a child with low-concentration topical tacrolimus ointment. J Dermatol 2007; 34: 114-116
34. Ginarte M, Toribio J. Vulvar lichen sclerosus successfully treated with topical tacrolimus. Eur J Obstet Gynecol Reprod Biol 2005; 123: 123-124
35. Goldstein AT, Marinoff SC, Christopher K. Pimecrolimus for the treatment of vulvar lichen sclerosus in a premenarchal girl. J Pediatr Adolesc Gynecol 2004; 17: 35-37 (Pubitemid 38315012)
36. Goldstein AT, Marinoff SC, Christopher K. Pimecrolimus for the treatment of vulvar lichen sclerosus: a report of 4 cases. J Reprod Med 2004; 49: 778-780 (Pubitemid 39431172)
37. Boms S, Gambichler T, Freitag M, et al. Pimecrolimus 1 % cream for anogenital lichen sclerosus in childhood. BMC Dermatol 2004; 4: 14
38. Luesley DM, Downey GP. Topical tacrolimus in the management of lichen sclerosus. BJOG 2006; 113: 832-834
39. Virgili A, Lauriola MM, Mantovani E, et al. Vulvar lichen sclerosus: 11 women treated with tacrolimus 0.1% ointment. Acta Derm Venereol 2007; 87: 69-72
40. Oskay T, Sczer HK, Genc C, et al. Pimecrolimus 1% cream in the treatment of vulvar lichen sclerosus in postmenopausal women. Int J Dermatol 2007; 46: 527-532
41. Nissi R, Eriksen H, Risteli J, et al. Pimecrolimus cream 1% in the treatment of lichen sclerosus. Gynecol Obstet Invest 2007; 63: 151-154
42. Hengge UR, Krause W, Hofmann H, et al. Multicentre, phase 2 trial on the safety and efficacy of topical tacrolimus ointment for the treatment of lichen sclerosus. Br J Dermatol 2006; 155: 1021-1028
43. Berger TG, Duvic M, Van Voorhees AS, et al. The use of topical calcineurin inhibitors in dermatology: safety concerns: report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol 2006; 54: 818-823
44. Callen J, Chamlin S, Eichenfield LF, et al. A systemic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol 2007; 156: 203-221
45. Kawashima M, Nakagawa H, Ohtsuki M, et al. Tacrolimus concentrations in blood during topical treatment of atopic dermatitis. Lancet 1996; 348: 1240-1241
46. Qureshi AA, Fischer MA. Topical calcineurin inhibitors for atopic dermatitis: balancing clinical benefit and possible risks. Arch Dermatol 2006; 142: 633-637
47. Stern RS. Topical calcineurin inhibitors labelling: putting the 'box' in per-spective. Arch Dermatol 2006; 142: 1233-1234
48. Topical tacrolimus and pimecrolimus: reports of malignancies. Curr Probl Pharmacovigilance 2006; 31: 1-2
49. Langeland T, Engh V. Topical use of tacrolimus and squamous cell carcinoma on the penis. Br J Dermatol 2005; 152: 183-185
50. Fischer G, Bradford J. Topical immunosuppressants, genital lichen sclerosus and the risk of squamous cell carcinoma: a case report. J Reprod Med 2007; 52: 329-331
51. Niwa Y, Terashima T, Sumi H. Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. Br J Dermatol 2003; 149: 960-967
52. Bilenchi R, Poggiali S, De Padova LA, et al. Human papilloma virus re-activation following topical tacrolimus therapy for anogenital lichen sclerosus. Br J Dermatol 2007; 156: 405-406
53. Lonsdale-Eccles AA, Velangi S. Herpes simplex of the vulva evoked by topical tacrolimus. Clin Exp Dermatol 2005; 30: 95-96
54. Kim YJ, Kang HY. Pigmentation after using topical tacrolimus to treat lichen sclerosus: possible role of stem cell factor. J Am Acad Dermatol 2007; 57: S1 25-27
55. Dalziel KL, Millard PR, Wojnarowska F. The treatment of vulval lichen sclerosus with a very potent topical steroid (clobetasol proprionate 0.05%) cream. Br J Dermatol 1991; 124: 461-464
56. Virgili A, Corazza M, Bianchi A, et al. Open study of topical 0.025% tretinoin in the treatment of vulval lichen sclerosus. J Reprod Med 1995; 40: 614-618
57. Ayhan A, Urman B, Yuce K, et al. Topical testosterone for lichen sclerosus. Int J Gynecol Obstet 1989; 30: 253-255
58. Lascano EF, Montes LF, Mazzini MA. Lichen sclerosus et atrophicus in childhood. Obstet Gynecol 1964; 24: 872-877
59. Bousema MT, Romppanem U, Geiger JM, et al. Acitretin in the treatment of severe lichen sclerosus et atrophicus of the vulva: a double blind, placebo controlled trial. J Am Acad Dermatol 1994; 30: 225-231
60. Cooper CM, Gao X-H, Powell JJ, et al. Does treatment of vulvar lichen sclerosus influence its prognosis? Arch Dermatol 2004; 140: 702-706
61. Simonart T, Lahaye M, Simonart J-M. Vulvar lichen sclerosus: effect of maintenance treatment with a moisturiser on the course of the disease. Menopause 2007; 15: 1-4
62. Powell JJ, Wajnarowska F. Lichen sclerosus. Lancet 1999; 353: 1777-1783
63. Carli P, Cattaneo A, De Magnis A, et al. Squamous cell carcinoma of the vulva and lichen sclerosus: a longitudinal cohort study.Eur J Cancer Prev 1995;4:491-495
64. Walkden V, Chia Y, Wojnarowska F. The association of squamous cell car-cinoma of the vulva and lichen sclerosus: implications for follow up. J Obstet Gynaecol 1997; 17: 551-553
65. Bunker CB, Neill S, Staughton RCD. Topical tacrolimus, genital lichen sclerosus, and risk of squamous cell carcinoma [letter]. Arch Dermatol 2004; 140: 1169
66. Edey K, Bisson D, Kennedy C. Topical tacrolimus in the management of lichen sclerosus [letter]. BJOG 2006; 113: 1482